Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies
ABSTRACT To review findings from pharmaco-epidemiological studies exploring antipsychotic (AP) drugs prescribing trends.
We retrieved original studies that explored AP prescribing trends in general population samples since 2000. For each study, we extracted information on sampling method, period, assessment of AP use and corresponding estimates (incidence rates, prevalence rates, pharmacy sales, prescription data) and diagnostic assessment.
Nearly all studies meeting the inclusion criteria (n = 17) showed an increase in AP prescriptions, mainly because of a dramatic rise in second-generation antipsychotics (SGAP) prescriptions. APs are often prescribed for non-psychotic disorders in adults as well as in children and adolescents.
Considering the growing number of persons from the general population exposed to APs, population studies assessing the risk/benefit ratio of SGAP use in disorders other than psychosis are necessary, particularly in children and adolescents.
- SourceAvailable from: Steffen Moritz[Show abstract] [Hide abstract]
ABSTRACT: The Psychiatric Symptom Rating Scales (PSYRATS) have demonstrated their usefulness for the dimensional assessment of hallucinations and delusions. However, there is no evaluated German version of the PSYRATS to date. Also, in spite of theoretical conceptions about "detaching" effects of antipsychotics, there are few consolidated findings about how core symptomatic aspects of schizophrenia change during antipsychotic treatment. The present study aimed to fill this gap. A total of 40 schizophrenic voice-hearers were interviewed three times during the course of six months using a newly developed German version of the PSYRATS with very good psychometric properties. At the same time, psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). In the longitudinal course, a general symptomatic decrease became apparent only for auditory hallucinations but not for delusions. Specifically, the loudness of the hallucinated voices as well as the associated distress decreased early, while other aspects of the hallucinations took more time to fade. In this study, the PSYRATS proved to be a valuable tool for measuring the change of specific symptom dimensions. However, our results only partially supported the notion of a general detachment from symptoms due to psychiatric treatment.Psychiatry Research 06/2011; 188(1):13-7. DOI:10.1016/j.psychres.2010.12.013 · 2.68 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Scientific medicine regards placebo prescription as a lack of treatment, a control condition required to validate new therapies. However, recent studies show that placebo treatments induce beneficial effects that are larger than those observed during spontaneous healing, especially regarding depression, anxiety and other mood disorders. Here we review this literature, including meta-analyses showing that, except for severely depressed patients, placebo treatments are as effective as antidepressants. Then, we review studies concerning the conditions that modulate the size of the placebo effect in depression. We emphasize studies showing that a neurobiological conception of depression, held either by patients or their physicians, impairs healing. These observations call for considering the placebo effect as resulting from an interpersonal relationship that should be interpreted in reference to the psychoanalytical concept of transference. During a placebo treatment, the patient exchanges the medical acknowledgement of his patient status for a temporary improvement of his symptoms, but his transference is not taken into account by his physician. Actually, psychodynamic and cognitive-behavioral psychotherapies induce lasting improvements compared to placebo or antidepressant treatments. According to our interpretation, when psychotherapists take care of patient transference, including its heavy emotive power, their patients become conscious of their unconscious repetitions stemming from childhood and are able to free themselves from them. We conclude by a few suggestions regarding the training of psychotherapists and the excessive medicalization of psychic distress.L &E cute volution Psychiatrique 04/2013; 78(2):327–340. DOI:10.1016/j.evopsy.2013.02.004 · 0.13 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: It has been informally observed that patients attending urology clinics specializing in overactive bladder and incontinence have high rates of psychiatric conditions. Hence, the evolution of the term “uropsychiatry” that describes the association between overactive bladder and incontinence with common psychiatric conditions including depression, anxiety, and sexual abuse. Epidemiologic and case-control studies have established links between these conditions. In addition, basic science and clinical pharmacologic studies of antidepressants and atypical antipsychotics provide evidence that dysregulation of neurotransmitters including norepinephrine, serotonin, and corticotropin releasing factor may be important in the pathophysiology underlying uropsychiatric disorders. Improved understanding of these complex interactions may help in the identification of novel targets that lead to improved treatments for patients with both urologic and psychiatric conditions.Current Bladder Dysfunction Reports 03/2012; 8(1). DOI:10.1007/s11884-012-0164-5